Back to search

Article

Ceftazidime-avibactam Versus Tigecycline for the Treatment of Carbapenem-resistant Klebsiella Pneumoniae-induced Pneumonia in Critically Ill Patients

2021-04-08

Abstract excerpt

<h4>Background: </h4> To assess the safety patterns and outcomes of ceftazidime-avibactam (CAZ-AVI) versus tigecycline (TGC) for the treatment of carbapenem-resistant Klebsiella pneumoniae (CRKP) pneumonia defined as either hospital-acquired pneumonia (HAP) or ventilator-associated pneumonia (VAP). <h4>Methods: </h4>: Clinical and microbiological cure rates, 28-day survival rates, and safety evaluation were compar...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
9d0b6d76-fe11-53d2-b6b1-d8e6b325dda4
DOI
10.21203/rs.3.rs-395732/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Ceftazidime-avibactam Versus Tigecycline for the Treatment of Carbapenem-resistant Klebsiella Pneumoniae-induced Pneumonia in Critically Ill PatientsDOI 10.21203/rs.3.rs-395732/v1
Comparison of meropenem-vaborbactam with ceftazidime-avibactam in the treatment of carbapenem-resistant Enterobacterales infectionsSemantic proximity
Efficacy and safety of newer antibiotics versus generic antibiotics for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia: a systematic review and meta-analysis of randomized controlled trialsSemantic proximity
Piperacillin-tazobactam should be preferred to third-generation cephalosporins to treat wild-type inducible AmpC-producing Enterobacteriaceae in critically ill patients with hospital or ventilator-acquired pneumonia. A propensity score-matched analysisSemantic proximity
Potentially effective antimicrobial treatment for pneumonia caused by isolates of carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii complex species: what can we expect in the future?Semantic proximity
Ceftazidime‐Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient SubgroupsSemantic proximity
Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation.Semantic proximity
Molecular epidemiology and risk factors for colistin- or tigecycline-resistant carbapenemase-producing Klebsiella pneumoniae bloodstream infection in critically ill patients during a 7-year period.Semantic proximity
Clinical Outcomes of Third-Generation Cephalosporins, Carbapenems, and Piperacillin-Tazobactam in the Treatment of AmpC- Associated Enterobacterales Species SepsisSemantic proximity
Compassionate use of meropenem/vaborbactam for infections caused by KPC-producing <i>Klebsiella pneumoniae</i>: a multicentre studySemantic proximity
Current Pattern and Clinico-Bacteriological Profile of Healthcare Associated Infections (HAI) in an ICU Setting: An Observational StudySemantic proximity
Hospital-Acquired Pneumonia: The Lebanese Societies for Pulmonary, Critical Care, and Infectious Diseases and Clinical Microbiology Joint GuidelinesSemantic proximity
Reversal of carbapenemase-producing Klebsiella pneumoniae epidemiology from blaKPC- to blaVIM-harbouring isolates in a Greek ICU after introduction of ceftazidime/avibactamSemantic proximity
Select a neighboring publication to make it the new centre.